Mirum Pharmaceuticals (MEX:MIRM) LT-Debt-to-Total-Asset: 0.36 (As of Mar. 2026)

What is Mirum Pharmaceuticals LT-Debt-to-Total-Asset?

Mirum Pharmaceuticals MEX:MIRM 46 LT-Debt-to-Total-Asset is 0.36 as of Mar. 2026. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN812.06. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Mirum Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.36.

Mirum Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2025 (0.46) to Mar. 2026 (0.36). It may suggest that Mirum Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Mirum Pharmaceuticals (MEX:MIRM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mirum Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Mirum Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals LT-Debt-to-Total-Asset Chart

Mirum Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.00

0.48

0.47

0.38

Mirum Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.46	0.44	0.40	0.38	0.36

46GF Score

Mirum Pharmaceuticals Inc MEX:MIRM

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Mirum Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Mirum Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	5713.443	/	15175.438
	=	0.38

Mirum Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	5796.179	/	16065.621
	=	0.36

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.36 mean?

Mirum Pharmaceuticals (MEX:MIRM) has a LT-Debt-to-Total-Asset of 0.36 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Mirum Pharmaceuticals and its competitors.

Is Mirum Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Mirum Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.36. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.

How does Mirum Pharmaceuticals' LT-Debt-to-Total-Asset compare to RYTM and SYRE?

Mirum Pharmaceuticals' LT-Debt-to-Total-Asset of 0.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Mirum Pharmaceuticals stock overvalued right now?

Mirum Pharmaceuticals (MEX:MIRM) has a current LT-Debt-to-Total-Asset of 0.36. The stock's GF Value™ is MXN812.06, compared to a current price of MXN1,256.12 — trading 54.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.36. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current LT-Debt-to-Total-Asset is 0.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 54.7% above its estimated GF Value™ of MXN812.06.

Key valuation signals for MEX:MIRM:

LT-Debt-to-Total-Asset: 0.36
GF Value™: MXN812.06 vs. price of MXN1,256.12 (54.7% above fair value)
GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies RYTM SYRE PTGX IMVT PTCT PCVX SRRK TGTX COGT CGON VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges MIRM:USA 08D:Germany

Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404

Website https://www.mirumpharma.com

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

46GF Score

Get the complete analysis for MEX:MIRM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12

Price

MXN812.06

GF Value

View MEX:MIRM Analysis

See LT-Debt-to-Total-Asset data for all stocks →